Loading
Loading
Healthcare
Executive compensation benchmarks for 17 public companies in the biological products, (no diagnostic substances) industry.
$13.4M
17
$33.2M
24:1
Median
$13,448,935
Average
$15,241,277
25th Percentile
$8,151,180
75th Percentile
$23,166,223
Minimum
$5,965,903
Maximum
$33,239,183
Avg Pay Ratio
24:1
Companies
17
Click any company to see full compensation breakdown
The median biological products, (no diagnostic substances) CEO compensation is $13,448,935, based on 17 public companies. The average is $15,241,277. Note that CEO compensation includes salary, bonus, stock awards, option awards, and other compensation.
Michael M. Morrissey of EXELIXIS, INC. is the highest paid biological products, (no diagnostic substances) CEO, with total compensation of $33,239,183 in FY2025.
The average CEO-to-median-employee pay ratio in the biological products, (no diagnostic substances) industry is 24:1. This means the average CEO earns 24 times what the median employee earns.
Data sourced from SEC filings (DEF 14A proxy statements). Last updated: May 31, 2026. Compensation figures are total annual compensation including salary, bonus, stock awards, and other compensation.
Compare CEO compensation across different industries or research specific companies.
| Company | CEO | Total Comp |
|---|---|---|
| EXELIXIS, INC. EXEL | Michael M. Morrissey | $33.2M |
| GILEAD SCIENCES, INC. GILD | Daniel P. O’Day | $28.4M |
| Amgen Inc. AMGN | Robert A. Bradway | $24.7M |
| BIOGEN INC. BIIB | Christopher A. Viehbacher | $23.6M |
| HALOZYME THERAPEUTICS, INC. HALO | Helen I. Torley | $23.2M |
| Moderna, Inc. MRNA | Stéphane Bancel | $15.6M |
| Revolution Medicines, Inc. RVMD | Mark A. Goldsmith | $14.7M |
| Vaxcyte, Inc. PCVX | Grant E. Pickering | $14.5M |
| NEUROCRINE BIOSCIENCES INC NBIX | Kyle W. Gano | $13.4M |
| Vericel Corp VCEL | Dominick Colangelo | $11.2M |
| Krystal Biotech, Inc. KRYS | Krish S. Krishnan | $10.4M |
| ADMA BIOLOGICS, INC. ADMA | Adam S. Grossman | $10.2M |
| BIO-TECHNE Corp TECH | Kim Kelderman | $8.2M |
| Vir Biotechnology, Inc. VIR | Marianne De Backer | $7.8M |
| ARGENX SE ARGX | Tim Van Hauwermeiren | $7.8M |
| REPLIGEN CORP RGEN | Olivier Loeillot | $6.1M |
| Cidara Therapeutics, Inc. CDTX | Jeffrey Stein | $6.0M |